CPHI 2026 – 23/07/2026
PCI Drug-Device 28/05/2026

Current Edition

ramusmedical
Regional News

Revance’s Botox rival turned away by FDA after inspectors flagged manufacturing ‘deficiencies’

Despite a pandemic delay and an FDA warning about quality control and record-keeping problems at a production site, Revance insisted it was optimistic the agency woul...
Continue Reading →
Regional News

As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it...
Continue Reading →
Quotient
CPHI 2026 – 20/07/2026